Surface-engineered nanoliposomes by chelating ligands for modulating the neurotoxicity associated with β-amyloid aggregates of alzheimer's disease

Pharmaceutical Research

Volumn 29, Issue 11, 2012, Pages 3075-3089

  Mufamadi, Maluta S ^a   Choonara, Yahya E ^a   Kumar, Pradeep ^a   Modi, Girish ^a   Naidoo, Dinesh ^a   Ndesendo, Valence M K ^b   Du Toit, Lisa C ^a   Iyuke, Sunny E ^c   Pillay, Viness ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b ST JOHN'S UNIVERSITY OF TANZANIA   (Tanzania)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

amyloid neurotoxicity; Alzheimer's disease; chelating ligands; surface engineered nanoliposomes; targeted delivery

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CHELATING AGENT; COPPER ACETATE; EDETIC ACID; HISTIDINE; LIGAND; LIPOSOME; NANOLIPOSOME; POLYMER; UNCLASSIFIED DRUG; ZINC ACETATE;

ALZHEIMER DISEASE; ARTICLE; BIOENGINEERING; CHELATION; CHEMICAL MODIFICATION; CHEMOMETRIC ANALYSIS; CONTROLLED STUDY; COVALENT BOND; EMULSION; INFRARED SPECTROSCOPY; MOLECULAR MODEL; NANOPHARMACEUTICS; NEUROTOXICITY; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN AGGREGATION; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CELL LINE, TUMOR; CHELATING AGENTS; COPPER; LIGANDS; LIPOSOMES; NANOPARTICLES; NEURONS; PARTICLE SIZE; PC12 CELLS; RATS; ZINC;

EID: 84867841702     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0770-0     Document Type: Article

References (49)

1. Cummings JH. Alzheimer's disease. N Engl J Med. 2004;351:56-67.
2. Brookmeyer R, Evans DA, Hebert L, et al. National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimer's & Dementia. 2011;7:61-73.
3. Iversen LL, Mortishire-Smith RJ, Pollack SL, et al. The toxicity in vitro of beta-amyloid protein. Biochem J. 1995;311(1):1-16.
4. Marino T, Russo N, Toscano N, et al. On the metal ion (Zn(II), Cu (II)) coordination with beta-amyloid peptide: DFT computational study. Interdiscipl Sci. 2010;2:57-69.
5. De Strooper B, Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci. 2000;113(11):1857-70.
6. Small DH, Mok SS, Bornstein JC. Alzheimer's disease and Aβ toxicity: from top to bottom. Nat Rev Neurosci. 2001;2(8):595-8.
7. Citron M. Beta-secretase as a target for the treatment of Alzheimer's disease. J Neurosci Res. 2002;70:373-9.
8. De Felice FG, Vieira MN, Saraiva LM, et al. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Aβ oligomerization. FASEB J. 2004;18:1366-72.
9. Lublin AL, Gandy S. Amyloid β oligemers: possible roles as key neurotoxicin in Alzheimer's disease. Mt Sinai J Med. 2010;77(43):43-9.
10. Bush AI, Tanzi RE. Therapeutics for Alzheimers disease based on the metal hypothesis. Neurotherapeutics. 2008;5(3):421-32.
11. Lovell MA, Robertson JD, Teesdale WJ, et al. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci. 1998;158(1):47-52.
12. Dong J, Atwood CS, Anderson VE, et al. Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochem J. 2003;42:2768-73.
13. Duce JA, Bush AI. Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics. Prog Neurobiol. 2010;92:1-18.
14. Zatta P, Drago D, Bolognin S, et al. Alzheimer's disease, metal ions and metal homeostatic therapy. Trends Pharmacol Sci. 2009;30(7):346-55.
15. Opazo C. Transition metals and Alzheimer's disease. Rev Esp Geriatr Gerontol. 2005;40(6):365-70.
16. Bush AI. Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging. 2002;23:1031-8.
17. Conway M, Holoman S, Jones L, et al. Selecting and using chelating agents. J Chem Eng. 1999;106(3):86-90.
18. Liu G, Men P, Kudo W, et al. Nanoparticle-chelator conjugates as inhibitors of Amyloid-β aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer Disease. Neurosci Lett. 2009;455(3):187-90.
19. Seely DMR, Wu P, Mills EJ. EDTA chelation therapy for cardiovascular disease: a systematic review. BMC Cardiovasc. 2005;5(32):1-6.
20. Nair NG, Perry G, Smith MA, et al. NMR studies of zinc, copper, and iron binding to histidine, the principal metal ion complexing site of amyloid-β peptide. J Alzheimer's Dis. 2010;20(1):57-66.
21. Chikha GG, Li WM, Schutze-Redelmeier MP, et al. Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids. Biochim Biophys Acta. 2002;1567(1-2):204-12.
22. Marcellini M, Di Ciommo V, Callea F, et al. Treatment of Wilson's disease with zinc from the time of diagnosis in pediatric patients: a single-hospital, 10-year follow-up study. J Lab Clin Med. 2005;145(3):139-43.
23. Shimizu N, Yamaguchi Y, Aoki T. Treatment and management of Wilson's disease. Pediatr Int. 1999;4(4):419-22.
24. Squitti R, Zito G. Anti-copper therapies in Alzheimer's disease: new concepts. Recent Pat CNS Drug Discov. 2009;4:209-19.
25. Popovic N, Brundin P. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. Int J Pharm. 2006;314(2):120-6.
26. Cui Z, Lockman PR, Atwood CS, et al. Novel d-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur J Pharm Biopharm. 2005;59:263-72.
27. Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. NeuroRx. 2005;2:99-107.
28. Liu GP, Men P, Harris PL, et al. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci Lett. 2006;406:189-93.
29. Atyabi F, Farkhondehfa A, Esmaeili F, et al. Preparation of pegylated nano-liposomal formulation containing SN-38: in vitro characterization and in vivo biodistribution in mice. Acta Pharm. 2009;59:133-44.
30. Modi G, Pillay V, Choonara YE. Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann N Y Acad Sci. 2010;1184:154-72.
31. Kizelsztein P, Ovadia H, Garbuzenko O, et al. Pegylated nanoliposomes remote-loaded with the antioxidant tempamine ameliorate experimental autoimmune encephalomyelitis. J Neuroimmunol. 2009;213:20-5.
32. Yigit MV, Mishra A, Tong R, et al. Inorganic mercury detection and controlled release of chelating agents from ion-responsive liposomes. Chem Biol. 2009;16:937-42.
33. Phachonpai W, Wattanathorn J, Muchimapura S, et al. Neuroprotective effect of quercetin encapsulated liposomes: a novel therapeutic strategy against Alzheimer's disease. Am J Appl Sci. 2010;7(4):480-5.
34. Ying X, Wen H, Lu WL, et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Contr Release. 2010;141:183-92.
35. Kamidate T, Hashimoto Y, Tani H, et al. Uptake of transition metal ions using liposome containing dicetylphosphate as a ligand. Anal Sci. 2002;18:273-6.
36. Suzuki R, Takizawa T, Negishi Y, et al. Gene delivery by combination of novel liposmal bubbles with perfluoropropane and ultrasound. J Contr Release. 2007;117:130-6.
37. Zhua J, Xue J, Guo Z, et al. Vesicle size and stability of biomimetic liposomes from 3′-Sulfo-Lewis a (SuLea)-containing glycolipids. Colloids Surf B Biointerfaces. 2007;58(2):242-9.
38. Verma DD, Verma S, Blume G, et al. Particle size of liposomes influences dermal delivery of substances into skin. Int J Pharm. 2003;258:141-51.
39. Yagi N, Ogawa Y, Kodaka M, et al. Preparation of functional liposomes with peptide ligands and their binding to cell membranes. Lipids. 2000;35:673-9.
40. Janssen AP, Schiffelers RM, ten Hagen TL, et al. Peptide-targeted PEG-liposome in anti-angiogenic therapy. Int J Pharm Pharm Sci. 2003;254(1):55-8.
41. Greene LA, Tischler AS. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. PNAS. 1973;73:2424-8.
42. Zhang LW, Yang J, Barron AR, et al. Endocytic mechanisms and toxicity of a functionalized fullerene in human cells. Toxicol Lett. 2009;191:149-57.
43. Kumar P, Pillay V, Choonara YE, et al. In silico theoretical molecular modeling for Alzheimer's disease: the nicotine-curcumin paradigm in neuroprotection and neurotherapy. Int J Mol Sci. 2011;12:694-724.
44. Weers JG, Scheuing DR. Characterization of viscoelastic surfactant mixtures, I: fourier transform infrared spectroscopic studies. Colloids Surf B: Biointerfaces. 1991;1(55):41-56.
45. Strozyk D, Launer LJ, Adlard PA, et al. Zinc and copper modulate Alzheimer Aβ levels in human cerebrospinal fluid. Neurobiol Aging. 2009;30(7):1069-77.
46. Choonara YE, Pillay V, Ndesendo VMK, et al. Polymeric emulsion and crosslink-mediated synthesis of super-stable nanoparticles as sustained-release anti-tuberculosis drug carriers. Colloids Surf B: Biointerfaces. 2011;87:243-54.
47. Lozano MM, Longo ML. Microbubbles coated with disaturated lipids and DSPE-PEG2000: phase behavior, collapse transitions, and permeability. Langmuir. 2009;25:3705-12.
48. Morgan DM, Dong JJ, Jacob J, et al. Metal switch for amyloid formation: insight into the structure of the nucleus. J Am Chem Soc. 2002;124:12644-5.
49. Daxiong H, Haiyan W, Yang Y. Molecular modeling of zinc and copper binding with Alzheimer's amyloid b-peptide. Biometals. 2008;21:189-96.